Price T Rowe Associates Inc Relmada Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $7,802 - $11,923	-3,146 Reduced 1.94%	159,290 $478,000
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $35,528 - $56,654	-16,004 Reduced 8.97%	162,436 $400,000
Q1 2023 May 15, 2023	SELL	$2.24 - $4.76 $20,202 - $42,930	-9,019 Reduced 4.81%	178,440 $404,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $19,740 - $326,036	-9,097 Reduced 4.63%	187,459 $654,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $508,721 - $1.03 Million	27,799 Added 16.47%	196,556 $7.28 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $184,668 - $339,565	11,192 Added 7.1%	168,757 $3.21 Million
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $2.63 Million - $4.25 Million	157,565 New	157,565 $4.25 Million
Q4 2021 Feb 14, 2022	SELL	$16.93 - $26.82 $136,405 - $216,088	-8,057 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.86 - $34.77 $176,126 - $280,141	8,057 New	8,057 $211,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.